Miriam Ricasoli

  • Citations Per Year
Learn More
Sorafenib improves overall survival and time to progression of advanced hepatocellular (aHCC) patients such as demonstrated in 2 phase III trials. However, aHCC patients’ outcome is still poor despite these results. In order to improve the efficacy of systemic treatment for aHCC, we evaluated the combination of sorafenib plus 5-fluorouacil infusion in a(More)
A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy Marzia Del Re, Fotios Loupakis, Cecilia Barbara, Laura Lombardo, Tiziana Latiano, Elena Zafarana, Stefano Cordio, Luisa Toffolatti, Miriam Ricasoli, Dario Giuffrida, Jennifer Vanoli, Samantha Di Donato, Federico(More)
  • 1